Metagenomi Therapeutics (MGX) Asset Writedowns and Impairment (2023 - 2025)
Metagenomi Therapeutics (MGX) posted quarterly Asset Writedowns and Impairment of $181000.0 for Q2 2025, down 34.18% year-over-year from $275000.0 in Q2 2024, and down 75.93% quarter-over-quarter from $752000.0 in Q4 2024.
Metagenomi Therapeutics (MGX) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Asset Writedowns and Impairment for 3 consecutive years, with $181000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Asset Writedowns and Impairment fell 34.18% year-over-year to $181000.0; the TTM figure through Sep 2025 stood at $933000.0 (up 206.91% YoY), while the FY2024 annual figure was $1.0 million, up 4430.43% from the prior year.
- Asset Writedowns and Impairment eased to $181000.0 in Q2 2025 per MGX's latest filing, from $752000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $752000.0 in Q4 2024 and bottomed at $4000.0 in Q1 2024.
- Historically, Asset Writedowns and Impairment has averaged $206166.7 across 3 years, with a median of $97500.0 in 2023.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment surged 5271.43% — and 2025, when it slumped 34.18%.
- Metagenomi Therapeutics' Asset Writedowns and Impairment stood at $14000.0 in 2023, then soared by 5271.43% to $752000.0 in 2024, then tumbled by 75.93% to $181000.0 in 2025.
- Business Quant data shows MGX's Asset Writedowns and Impairment at $181000.0 in Q2 2025, $752000.0 in Q4 2024, and $11000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 181,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 181,000.00 |
| Dec 31, 2024 | 752,000.00 |
| Dec 31, 2024 | 752,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |